SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Highlights Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Market Closed - Hong Kong S.E. Other stock markets 09:08:13 24/06/2024 BST			5-day change	1st Jan Change
171 ^HKD	-1.04%		-0.70%	+66.18%

06-21	Sichuan Kelun-Biotech Directors Approve Full Circulation of H-Shares	MT
06-18	Hong Kong Shares Fall on Weak Economic Data, Trade Tensions; Wuhan Youji Surges 27% in Trading Debut	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sichuan Kelun-Biotech Directors Approve Full Circulation of H-Shares	06-21	MT
Hong Kong Shares Fall on Weak Economic Data, Trade Tensions; Wuhan Youji Surges 27% in Trading Debut	06-18	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives Clinical Trial Notice Approving the Investigational New Drug Application for the Innovative Drug SKB518	06-17	CI
Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO	05-24	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting	05-23	CI
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares	05-08	MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%	05-06	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Cleared to Start Phase 2 by the US Food and Drug Administration	05-03	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024	04-08	CI
Kelun-Biotech Shrinks Loss by 7% in 2023	03-26	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration	03-13	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration	03-11	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC	02-23	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration	12-10	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product	11-30	CI
Kelun-Biotech Biopharma Gets Filing Notice for H Share Full Circulation	11-14	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Provides Update on Collaboration with Merck Sharp & Dohme LLC	23/10/23	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Abstract for Oral Presentation of the Study Results from Core Product SKB264 (MK-2870) Published on the Website of the 2023 ESMO Congress	16/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Highlights

Filters